Table 4.

Outcome events in the population. Results of multivariate analysis

	LVH	Hazard Ratio
		D 110 mg vs. warfarin	P-value	P value for interaction	D 150 mg vs. warfarin	P-value	P-value for interaction
Stroke or systemic embolism	Absent	1.01 (0.75–1.36)	0.9500	0.0362	0.66 (0.47–0.92)	0.0145	0.4186
	Present	0.55 (0.34–0.89)	0.0147		0.51 (0.31–0.84)	0.0079
Any stroke	Absent	1.03 (0.75–1.41)	0.8453	0.0247	0.67 (0.47–0.95)	0.0263	0.2409
	Present	0.53 (0.32–0.86)	0.0112		0.46 (0.28–0.78)	0.0035
All-cause death	Absent	0.85 (0.69–1.05)	0.1374	0.9020	0.79 (0.63–0.98)	0.0312	0.4560
	Present	0.87 (0.65–1.17)	0.3541		0.90 (0.68–1.21)	0.4397
Vascular death	Absent	0.80 (0.60–1.05)	0.1123	0.5388	0.84 (0.63–1.11)	0.2163	0.7872
	Present	0.91 (0.66–1.27)	0.5821		0.79 (0.56–1.11)	0.1715

Adjusted for the single components of the CHA₂DS₂VASc score (congestive heart failure, hypertension, age, diabetes, prior stroke, coronary artery disease or peripheral arterial disease, gender), body mass index, current smoking at entry, glomerular filtration rate, use of digoxin at entry, valvular heart disease at entry, permanent AF at entry, randomized treatment, LVH, treatment, LVH x treatment interaction.

LVH, left ventricular hypertrophy; D, dabigatran; AF, atrial fibrillation.